Webinar: 3D High-Content Screening of Organoids for Drug Discovery

Over the past several years there has been a boom in concerted multidisciplinary efforts by scientists and biomedical engineers with a vision of developing 3D ex vivo tissue models of human organ function, anatomy and disease - referred to as organoid, organotypic, or spheroid. Organoids are well documented to better recapitulate aspects of in vivo organ function and human disease.

This webinar will describe the marriage of 3D organoids and high-content screening (HCS) to discover targeted drug therapies effective against the malignant phenotype in colorectal cancer (CRC). Our CRC tumor organoid model features an innovative dual reporter of epithelial-mesenchymal transition (EMT), including: E-cadherin promoter red fluorescent protein and vimentin promoter green fluorescent protein cloned into a single pCDH1 lentiviral vector.

We will also describe a robust methodology for automated tumor organoid culture and validated 3D high-content analysis algorithms. Using these approaches we have screened a focused library of 3,000 small molecule compounds and have identified and validated hits that promote the reversion of EMT in CRC.

Daniel V. LaBarbera, PhD
Associate Professor of Drug Discovery and Medicinal Chemistry
University of Colorado Anschutz Medical Campus
Skaggs School of Pharmacy and Pharmaceutical Sciences
Joe Trask
Senior Field Applications Scientist
In this webinar, learn about:
  • 3D tumor organoids, colorectal cancer biology and EMT biology
  • Automated 3D organoid culture methodologies for high-throughput drug discovery
  • 3D High-content analysis algorithm approaches for HCS
  • HCS using an innovative phenotypic EMT dual reporter in live CRC tumor organoids

Watch Now